BRCA1 and neoplasm: Patient 6 was found to have a mutation in FGFR2 (c.1364C>T p.T455M MV; VAF = 49.7%) in ctDNA that was not previously present in tumor tissue, for which several agents have been shown to demonstrate activity in advanced, refractory tumors harboring aberrations in FGFR 1-3.31-33 This patient was treated with pemigatinib, an FGFR2 inhibitor, and achieved a durable, objective response.33 Patient 9 was found to have a mutation in BRCA1 (c.2029_2030delinsTT p.G677L MV; VAF = 4.8%) in ctDNA that was not previously present in tumor tissue.